These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 38191918)

  • 1. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.
    Iorio R
    Nat Rev Neurol; 2024 Feb; 20(2):84-98. PubMed ID: 38191918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
    Bokoliya SC; Kumar VP; Nashi S; Polavarapu K; Nalini A; Patil SA
    Clin Chim Acta; 2018 Nov; 486():34-35. PubMed ID: 30006288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.
    Morren J; Li Y
    Muscle Nerve; 2018 Sep; 58(3):344-358. PubMed ID: 29461627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
    Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
    Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
    Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
    Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
    PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
    Hurst RL; Gooch CL
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylcholinesterase inhibitors in MG: to be or not to be?
    Punga AR; Stålberg E
    Muscle Nerve; 2009 Jun; 39(6):724-8. PubMed ID: 19260048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
    Lazaridis K; Tzartos SJ
    Front Immunol; 2020; 11():212. PubMed ID: 32117321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study.
    Modoni A; Mastrorosa A; Spagni G; Evoli A
    Clin Neurophysiol; 2021 Aug; 132(8):1845-1849. PubMed ID: 34147009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
    Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
    Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen specific B cells in myasthenia gravis patients.
    Takata K; Kinoshita M; Mochizuki H; Okuno T
    Immunol Med; 2020 Jun; 43(2):65-71. PubMed ID: 32046601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to agrin in myasthenia gravis patients.
    Zhang B; Shen C; Bealmear B; Ragheb S; Xiong WC; Lewis RA; Lisak RP; Mei L
    PLoS One; 2014; 9(3):e91816. PubMed ID: 24632822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
    Mori S; Shigemoto K
    Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.
    Koneczny I; Herbst R
    Cells; 2019 Jul; 8(7):. PubMed ID: 31269763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K; Konishi T; Ohta M
    Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.